Drugs / hTERT/Survivin Multi-Peptide Vaccine
hTERT/Survivin Multi-Peptide Vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00573495 | Nov 2007 → Jul 2011 | breast carcinoma | University of Pennsylvania | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | hTERT/Survivin Multi-Peptide Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00573495 ↗ |
| Modality | Vaccine | “hTERT Multi-Peptide Vaccine is made up of 1540 hTERT peptide and cryptic peptides” NCT00573495 ↗ |
| Route | Subcutaneous | “100 mcg subcutaneous every 2 weeks four times, then monthly up to 28 vaccinations” NCT00573495 ↗ |
| Target | TERT | “Targeting hTERT immunologically” NCT00573495 ↗ |